Royalty Pharma PLC (MEX:RPRX)
MXN 528.5 0 (0%) Market Cap: 243.55 Bil Enterprise Value: 363.97 Bil PE Ratio: 10.43 PB Ratio: 1.73 GF Score: 75/100

Royalty Pharma PLC at Citi BioPharma Conference (Virtual) Transcript

Sep 09, 2021 / 02:40PM GMT
Release Date Price: MXN801
Andrew Simon Baum
Citigroup Inc., Research Division - Global Head of Healthcare Research and MD

So welcome back, delighted to introduce our next session with the management of Royalty Pharma. Introducing a former colleague, Chris Hite, now Vice Chairman of Royalty; and Terrance Coyne, Chief Financial Officer of Royalty Pharma, which we participated in the IPO earlier last year actually.

So on that note, before we get into Q&A and because it is a relatively unique business model, which not all the investor base is familiar with, we're going to spend a little bit of time summarizing the structure, the strategy and the outlook for the company before we go to the Q&A. So handing it over to Terrance and Chris to take you on [aboard] that you like. Thank you for joining us again.

Christopher Hite
Royalty Pharma plc - Vice Chairman & Executive VP

Thank you, Andrew, and good afternoon, everyone. It is a pleasure to be here to discuss Royalty Pharma and share why we are so excited about the future of our business. On this slide, you can see our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot